Vancomycin dosing in patients on intermittent hemodialysis. - Wikidata - wikimedia - TriplyDB

Vancomycin dosing in patients on intermittent hemodialysis.

Vancomycin dosing in patients on intermittent hemodialysis.

http://www.wikidata.org/entity/Q37845424

about

Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study Vancomycin therapeutics and monitoring: a contemporary approach.Vancomycin: the tale of the vanquisher and the pyrrhic victory.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis Aminoglycoside impregnated cement spacer precipitating acute kidney injury requiring hemodialysis.Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients.Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis

P2860

Q34478074-B903432A-D14F-43B3-8BB1-F2EA2A27942B Q36116970-D8EEC7A2-0398-431B-95E7-526D6FD186F6 Q36454724-27AEC440-F276-42A4-ADF9-F3A8AE16AE9E Q38062923-F371322D-3D64-4457-87E7-1C19BCC55264 Q38542797-EFE14E36-753D-4B1C-AE7E-05724C45030B Q38545589-FBF2D1B9-282F-4EE4-A5BB-FE51C6DD0415 Q39203427-0421F10C-C950-4533-92CE-6216C66D57CC Q40111722-3A0457F0-2A6C-46C5-AE94-11CE167CBC0A Q40499611-5653FA04-7539-4791-9886-C31C20ABF1C3 Q57238274-CBDC9AEE-3D41-433C-8253-C9BB1CE66641

P2860

Vancomycin dosing in patients on intermittent hemodialysis.

http://www.wikidata.org/entity/Q37845424

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Vancomycin dosing in patients on intermittent hemodialysis.

@en

Vancomycin dosing in patients on intermittent hemodialysis.

@nl

type

label

Vancomycin dosing in patients on intermittent hemodialysis.

@en

Vancomycin dosing in patients on intermittent hemodialysis.

@nl

prefLabel

Vancomycin dosing in patients on intermittent hemodialysis.

@en

Vancomycin dosing in patients on intermittent hemodialysis.

@nl

P1433

Q37845424-808E2EB7-980B-44D7-AA79-3BA71ADE4BA8

P1476

Q37845424-8422F08B-2164-46AE-8556-F69BE26FA2EC

P2093

Q37845424-130ABEB2-98D7-4151-8963-C5DBA8D595E5

Q37845424-E8C15723-9604-4487-8546-163B3E26B5CD

P2860

Q37845424-078EF295-B1A7-4EDA-B2DE-E85A671874A1

Q37845424-0DE403F5-CDB8-4B19-8B7A-BA20C36FA175

Q37845424-1881E221-C21D-46D9-972E-EF54538A3DEC

Q37845424-1F9B69E5-9630-48FB-AFD8-E28C789D43AA

Q37845424-20EBF26F-8CD5-4893-A206-71B9A0A83CA9

Q37845424-23ED612F-2B92-490C-AFC2-EC2F9DEB339E

Q37845424-33B4F867-E0FC-4FDB-927E-F3B8843005CC

Q37845424-349B4E6B-E7DD-4588-81B1-A57160AB41A4

Q37845424-42CE3714-7BBF-4B62-8553-2A630F8B5F9D

Q37845424-500B5A34-AEB2-48A8-9227-23EC1FBEDF0D

P304

Q37845424-3D3B01B2-DA4E-4704-A492-0FE4070F6687

P31

Q37845424-E484F403-1924-4E53-83F0-ACE266CB8790

P356

Q37845424-C46BA00E-49A6-4D84-9384-98FF5AF503F2

P433

Q37845424-3635BDBF-AD41-4420-A982-3E98E47A9917

P478

Q37845424-4145F55D-086B-42CE-A81F-B895A74B4A19

P577

Q37845424-16570E4C-B87F-44EE-B505-F76F5642FFB8

P698

Q37845424-76C1DD74-C8FA-4CC6-BBA4-57E5B950664D

P356

J.1525-139X.2010.00803.X

P1433

Seminars in Dialysis

P1476

Vancomycin dosing in patients on intermittent hemodialysis.

@en

P2093

An S De Vriese

http://www.w3.org/2001/XMLSchema#string

Stefaan J Vandecasteele

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical review: use of vancomycin in haemodialysis patients

Vancomycin: a history.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Vancomycin pharmacokinetics in normal and morbidly obese subjects

Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

The pharmacokinetic and pharmacodynamic properties of vancomycin.

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Drug dosing considerations in alternative hemodialysis.

P304

50-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1525-139X.2010.00803.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21338394

http://www.w3.org/2001/XMLSchema#string